{"id":50178,"date":"2025-12-08T21:32:33","date_gmt":"2025-12-08T13:32:33","guid":{"rendered":"https:\/\/flcube.com\/?p=50178"},"modified":"2025-12-08T21:32:34","modified_gmt":"2025-12-08T13:32:34","slug":"shanghai-pharma-x842-deal-termination-with-sinorda","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50178","title":{"rendered":"Shanghai Pharma X842 Deal Termination with Sinorda"},"content":{"rendered":"\n<p><strong>Shanghai Pharmaceuticals Holding Co., Ltd.<\/strong> (SPH, <a href=\"https:\/\/www.google.com\/finance\/quote\/2607:HKG\">HKG: 2607<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/601607:SHA\">SHA: 601607<\/a>)\u00a0 announced the termination of its collaboration with <strong>Sinorda Biotechnology<\/strong> on the innovative gastric acid blocker <strong>X842<\/strong> through friendly negotiations. The original agreement, signed in October\u202f2021, involved a potential transaction value of <strong>RMB\u202f690\u202fmillion<\/strong> (excluding sales royalties). Sinorda will refund <strong>RMB\u202f110\u202fmillion<\/strong> plus development milestone fees at <strong>3% annualized interest<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-termination-details-amp-financial-terms\">Termination Details &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Agreement Element<\/th><th>Original Terms<\/th><th>Termination Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Execution Date<\/strong><\/td><td>08\u202fOct\u202f2021<\/td><td>08\u202fDec\u202f2025 (termination)<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>Up to RMB\u202f690\u202fmillion (excluding royalties)<\/td><td>Refund of RMB\u202f110\u202fmillion initial payment + milestone fees<\/td><\/tr><tr><td><strong>Interest Rate<\/strong><\/td><td>Not applicable<\/td><td>3% annualized on refunded amounts<\/td><\/tr><tr><td><strong>Product Rights<\/strong><\/td><td>X842 rights in China<\/td><td>Rights revert to Sinorda; agreement ceases legal binding<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-x842-p-cab\">Product Profile: X842 P-CAB<\/h2>\n\n\n\n<p><strong>Mechanism of Action:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Next-generation <strong>potassium ion competitive acid blocker (P-CAB)<\/strong><\/li>\n\n\n\n<li><strong>Rapid onset<\/strong> of acid suppression<\/li>\n\n\n\n<li><strong>Strong and durable<\/strong> therapeutic effect<\/li>\n\n\n\n<li><strong>Few adverse reactions<\/strong> compared to proton pump inhibitors (PPIs)<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Context:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Addresses unmet need in gastroesophageal reflux disease (GERD) and peptic ulcer disease<\/li>\n\n\n\n<li>P-CAB class gaining market share vs. traditional PPIs in China<\/li>\n\n\n\n<li>No domestic P-CAB approvals prior to 2023; growing market valued at <strong>\u00a53\u202fbillion<\/strong> (\u2248\u202fUS$420\u202fmillion)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-termination\">Strategic Rationale for Termination<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>External Market Assessment<\/strong>: Shanghai Pharma cited comprehensive evaluation of market conditions and competitive landscape<\/li>\n\n\n\n<li><strong>Business Development Alignment<\/strong>: Decision reflects overall strategic portfolio prioritization<\/li>\n\n\n\n<li><strong>Pipeline Repositioning<\/strong>: Company may redirect resources to higher-priority assets or therapeutic areas<\/li>\n\n\n\n<li><strong>Financial Recovery<\/strong>: RMB\u202f110\u202fmillion refund improves cash position; 3% interest partially compensates for development costs incurred<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-legal-amp-operational-implications\">Legal &amp; Operational Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Agreement Status<\/strong>: Automatically terminates; no ongoing legal obligations for either party<\/li>\n\n\n\n<li><strong>Technology Rights<\/strong>: X842 rights revert fully to Sinorda Bio, which may seek new partners<\/li>\n\n\n\n<li><strong>Development Halt<\/strong>: Shanghai Pharma will cease all X842-related development and registration activities<\/li>\n\n\n\n<li><strong>Market Impact<\/strong>: Removes potential P-CAB competitor from Shanghai Pharma\u2019s near-term pipeline<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the financial impact of the termination and Shanghai Pharma\u2019s future pipeline strategy. Actual outcomes may differ due to market conditions, competitive dynamics, and strategic decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/601607_20251206_78H8.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 601607_20251206_78H8.\"><\/object><a id=\"wp-block-file--media-c8ce0c1d-62c8-4bf6-bb02-b93b49e38871\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/601607_20251206_78H8.pdf\">601607_20251206_78H8<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/601607_20251206_78H8.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c8ce0c1d-62c8-4bf6-bb02-b93b49e38871\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607)\u00a0 announced the termination of its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50181,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[890,891,196,2629],"class_list":["post-50178","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals","tag-sinorda-biomedicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Pharma X842 Deal Termination with Sinorda - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607)\u00a0 announced the termination of its collaboration with Sinorda Biotechnology on the innovative gastric acid blocker X842 through friendly negotiations. The original agreement, signed in October\u202f2021, involved a potential transaction value of RMB\u202f690\u202fmillion (excluding sales royalties). Sinorda will refund RMB\u202f110\u202fmillion plus development milestone fees at 3% annualized interest.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50178\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharma X842 Deal Termination with Sinorda\" \/>\n<meta property=\"og:description\" content=\"Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607)\u00a0 announced the termination of its collaboration with Sinorda Biotechnology on the innovative gastric acid blocker X842 through friendly negotiations. The original agreement, signed in October\u202f2021, involved a potential transaction value of RMB\u202f690\u202fmillion (excluding sales royalties). Sinorda will refund RMB\u202f110\u202fmillion plus development milestone fees at 3% annualized interest.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50178\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T13:32:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T13:32:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0807.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharma X842 Deal Termination with Sinorda\",\"datePublished\":\"2025-12-08T13:32:33+00:00\",\"dateModified\":\"2025-12-08T13:32:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178\"},\"wordCount\":337,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0807.webp\",\"keywords\":[\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\",\"Sinorda Biomedicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50178#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50178\",\"name\":\"Shanghai Pharma X842 Deal Termination with Sinorda - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0807.webp\",\"datePublished\":\"2025-12-08T13:32:33+00:00\",\"dateModified\":\"2025-12-08T13:32:34+00:00\",\"description\":\"Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607)\u00a0 announced the termination of its collaboration with Sinorda Biotechnology on the innovative gastric acid blocker X842 through friendly negotiations. The original agreement, signed in October\u202f2021, involved a potential transaction value of RMB\u202f690\u202fmillion (excluding sales royalties). Sinorda will refund RMB\u202f110\u202fmillion plus development milestone fees at 3% annualized interest.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50178\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0807.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0807.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Pharma X842 Deal Termination with Sinorda\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50178#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharma X842 Deal Termination with Sinorda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharma X842 Deal Termination with Sinorda - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607)\u00a0 announced the termination of its collaboration with Sinorda Biotechnology on the innovative gastric acid blocker X842 through friendly negotiations. The original agreement, signed in October\u202f2021, involved a potential transaction value of RMB\u202f690\u202fmillion (excluding sales royalties). Sinorda will refund RMB\u202f110\u202fmillion plus development milestone fees at 3% annualized interest.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50178","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharma X842 Deal Termination with Sinorda","og_description":"Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607)\u00a0 announced the termination of its collaboration with Sinorda Biotechnology on the innovative gastric acid blocker X842 through friendly negotiations. The original agreement, signed in October\u202f2021, involved a potential transaction value of RMB\u202f690\u202fmillion (excluding sales royalties). Sinorda will refund RMB\u202f110\u202fmillion plus development milestone fees at 3% annualized interest.","og_url":"https:\/\/flcube.com\/?p=50178","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T13:32:33+00:00","article_modified_time":"2025-12-08T13:32:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0807.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50178#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50178"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharma X842 Deal Termination with Sinorda","datePublished":"2025-12-08T13:32:33+00:00","dateModified":"2025-12-08T13:32:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50178"},"wordCount":337,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50178#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0807.webp","keywords":["HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals","Sinorda Biomedicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50178#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50178","url":"https:\/\/flcube.com\/?p=50178","name":"Shanghai Pharma X842 Deal Termination with Sinorda - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50178#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50178#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0807.webp","datePublished":"2025-12-08T13:32:33+00:00","dateModified":"2025-12-08T13:32:34+00:00","description":"Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607)\u00a0 announced the termination of its collaboration with Sinorda Biotechnology on the innovative gastric acid blocker X842 through friendly negotiations. The original agreement, signed in October\u202f2021, involved a potential transaction value of RMB\u202f690\u202fmillion (excluding sales royalties). Sinorda will refund RMB\u202f110\u202fmillion plus development milestone fees at 3% annualized interest.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50178#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50178"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50178#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0807.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0807.webp","width":1080,"height":608,"caption":"Shanghai Pharma X842 Deal Termination with Sinorda"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50178#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharma X842 Deal Termination with Sinorda"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0807.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50178"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50178\/revisions"}],"predecessor-version":[{"id":50182,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50178\/revisions\/50182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50181"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}